Form 4: Aligos Therapeutics Director James Scopa Executes Option Exchange Program
SEC Form 4
Director James Scopa participated in Aligos Therapeutics' option exchange program, canceling an existing option and receiving a replacement option with a lower exercise price.
Summary
- On February 27, 2024, Aligos Therapeutics director James Scopa participated in the company's option exchange program.
- Scopa's existing option for 30,000 shares, granted on April 26, 2021, with an exercise price of $29.10, was canceled.
- In exchange, on February 28, 2024, Scopa received a replacement option for 8,823 shares with an exercise price of $0.96 per share.
- The replacement option vests one year from the grant date, contingent upon Scopa's continued service with Aligos Therapeutics.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing detailing an option exchange, with neutral sentiment.
Positives
- The option exchange program may incentivize the director with a lower exercise price.
Industry Context
Option exchange programs are sometimes used to re-incentivize employees or directors, particularly when the stock price has fallen significantly below the original option exercise price.
Stakeholder Impact
- The option exchange may have a minor dilutive effect on existing shareholders.
Key Dates
| Date | Description |
|---|---|
| 04/26/2021 | Original grant date of the canceled option for 30,000 shares. |
| 02/27/2024 | Date of cancellation of the original option. |
| 02/28/2024 | Date of grant of the replacement option for 8,823 shares. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.